Vulnerability · CVE-2025-30387
Improper limitation of a pathname to a restricted directory ('path traversal') in Azure allows an unauthorized attacker to elevate privileges over a network.
Published May 13, 2025 · catalog updated Feb 13, 2026 · Microsoft Azure AI Document Intelligence Studio
Check if you run it
No confirmed exploitation is on record for CVE-2025-30387. EPSS is 1.25%. Act only if a listed version of Microsoft Azure AI Document Intelligence Studio is installed.
Gaps on this record
- No vendor fix or required action is stored. Compare the linked advisory before you change production.
- Severity
- Critical9.8
- Known exploitation
- Not in CISA/VulnCheck KEV
- EPSS
- 1.25%
- Remediation
- Version ranges on file
- Affected products
- vendor Microsoft Azure AI Document Intelligence Studio 1.0.0 <1.0.03019.1-official-7241c17a
Improper limitation of a pathname to a restricted directory ('path traversal') in Azure allows an unauthorized attacker to elevate privileges over a network.
Are you affected?
Enter the version you run. The result uses only the ranges stored on this record.
The check returns affected, not affected, or incomplete. It does not guess a version that is missing from the record.
- vendor Microsoft Azure AI Document Intelligence Studio 1.0.0 <1.0.03019.1-official-7241c17a1.0.0 <1.0.03019.1-official-7241c17a
How to fix CVE-2025-30387
Recommended remediation
Affected version ranges suggest a fixed boundary. Verify against the vendor advisory for your release.
Official advisories
What to do
Three questions, each answered from this record only. Confirm the vendor advisory before you patch.
Should you patch?
No confirmed exploitation is on record for CVE-2025-30387. EPSS is 1.25%. Act only if a listed version of Microsoft Azure AI Document Intelligence Studio is installed.
Which versions are affected?
Compare what you have installed with Microsoft Azure AI Document Intelligence Studio 1.0.0 <1.0.03019.1-official-7241c17a 1.0.0 <1.0.03019.1-official-7241c17a. Compare the installed version with the linked vendor advisory before you change production.
What should an analyst verify?
No weakness class is stored. EPSS 1.25%. There is no CISA KEV listing. No Exploit-DB or Metasploit reference is linked. Use the source links for the original advisory.
Code
The project this record applies to. Exploit listings stay in References.
No public source repository is identified for this product.
Timeline
Detection, updates, and resolution for this record.
May 13, 2025 · EUVD
Detected
Improper limitation of a pathname to a restricted directory ('path traversal') in Azure allows an unauthorized attacker to elevate privileges over a network.
Feb 13, 2026 · EUVD
Updated
Improper limitation of a pathname to a restricted directory ('path traversal') in Azure allows an unauthorized attacker to elevate privileges over a network.
Sources
- CVE.orgVulnerability recordCVE-2025-30387
Official CVE identifier
cve.org - FIRST EPSSExploitation probabilityCVE-2025-30387
30-day exploitation probability 1.2%
first.org - EUVDVulnerability recordEUVD-2025-14449
Improper limitation of a pathname to a restricted directory ('path traversal') in Azure allows an unauthorized attacker to elevate privileges over a network.
euvd.enisa.europa.eu
References
Freshness
Last verified in this catalog Oct 18, 2026. Significant claims (KEV, EPSS, CVSS, affected ranges) come from the source rows above — open the original publisher for the authoritative advisory.